by Malavige GN, Sjö P, Singh K, Piedagnel JM, Mowbray C, Estani S, Chee Loon Lim S, Siquierra AM, Ogg GS, Fraisse L, Ribeiro I. PLOS Global Public Health 2023, 3(12): e0002598. doi: 10.1371/journal.pgph.0002598
Summary: Dengue is the most rapidly emerging mosquito-borne infection, overwhelming heath care facilities in endemic countries. Previously a predominantly childhood illness, dengue now affects mostly adults in many countries, with higher incidence of severe disease and mortality in pregnant women and those with comorbidities. While novel vector control methods and vaccines have shown promising results, we urgently need safe and effective treatments to prevent disease progression. Several novel drugs are being evaluated, either directed against the virus or inhibiting host mediators. In this review, the authors discuss the likely impact of changes in vector densities and population demographics, increases in infection rates, and the use of vaccines on the landscape of dengue infections.
